International Conference on Intelligent Systems（ICIS2005，2005年国际智能系统大会）于2005年12月1-3日在马来西亚吉隆坡举行。此次会议由马来西亚高等教育部批准，马来西来国家石油公司Petronas主赞助，Universiti Teknologi Petr...International Conference on Intelligent Systems（ICIS2005，2005年国际智能系统大会）于2005年12月1-3日在马来西亚吉隆坡举行。此次会议由马来西亚高等教育部批准，马来西来国家石油公司Petronas主赞助，Universiti Teknologi Petronas主办。参加会议的有来自中国、美国、日本、英国、马来西亚、印度等30个国家的200余篇论文作者及相关领域的研究人员。马来西来高等教育部部长Y．B．Dato’Sri Dr Haji Shafie Hj．Mohd Salleh亲临开幕式并致欢迎辞。展开更多
创新是一个民族进步的灵魂,是国家兴旺发达的不竭动力。2017年创新研究国际会议（The International Conference on Innovation Studies,ICIS2017）将于2017年6月24—26日在清华大学经济管理学院召开。本会议由清华大学技术创新研究中...创新是一个民族进步的灵魂,是国家兴旺发达的不竭动力。2017年创新研究国际会议（The International Conference on Innovation Studies,ICIS2017）将于2017年6月24—26日在清华大学经济管理学院召开。本会议由清华大学技术创新研究中心主任陈劲教授发起,国际创新学研究领域的著名领军学者、＂领先用户＂概念提出者Eric von Hippel教授作为特约嘉宾,将主持＂开放式创新与用户创新分会＂（1天）。展开更多
目的:本研究目的旨在探讨抗PD-1/PD-L1 (程序性细胞死亡蛋白-1,Programmed cell death-1/程序性死亡配体-1,Programmed death-ligand 1)治疗后发生心血管毒性死亡的风险因素,并以此构建预测模型。方法:本研究为单中心回顾性研究,通过系...目的:本研究目的旨在探讨抗PD-1/PD-L1 (程序性细胞死亡蛋白-1,Programmed cell death-1/程序性死亡配体-1,Programmed death-ligand 1)治疗后发生心血管毒性死亡的风险因素,并以此构建预测模型。方法:本研究为单中心回顾性研究,通过系统性回顾方法筛选2018年10月至2023年10月在青岛大学附属医院接受抗PD-1/PD-L1免疫治疗后的2665例实体肿瘤患者的病例资料观察180天,其中发生心血管毒性的33例,根据是否发生抗PD-1/PD-L1治疗心血管毒性死亡为结局,以是否发生死亡分为死亡组和存活组。采用单因素Cox回归分析其风险因素并控制相关混杂因素后构建预测模型绘制列线图。最后,利用受试者工作特征曲线(Receiver Operating Characteristic, ROC)、决策曲线分析法(Decision Curve Analysis, DCA)、校准曲线(Calibration Curve, CC)进行内部评价和内部验证。结果:1) 淋巴细胞计数、单核细胞计数、血小板计数、合并糖尿病、免疫检查点抑制剂种类、彩超室壁运动异常在心血管毒性存活组和死亡组间的差异均有统计学意义(均p Purpose: This study aimed to investigate risk factors for death from cardiovascular toxicity following anti-PD-1/PD-L1 therapy and develop a predictive model. Methods: This study was a single-center retrospective study, which screened the case data of 2665 patients with solid tumors after receiving anti-PD-1/PD-L1 immunotherapy at the Affiliated Hospital of Qingdao University for 180 days of observation by a systematic retrospective method, 33 cases of cardiovascular toxicity, and the outcome was based on whether or not death from cardiovascular toxicity of anti-PD-1/PD-L1 therapy occurred as the outcome categorized into death and survival groups. A one-way Cox regression analysis was used to analyze the risk factors and control for relevant confounders, and a predictive model was constructed to draw a column-line graph. Finally, Receiver Operating Characteristic (ROC), Decision Curve Analysis (DCA), and Calibration Curve (CC) were used for internal evaluation and internal validation. Results: 1) Lymphocyte, Platelet, Diabetes, Types of immune checkpoint inhibitors, Echocardiographic ventricular wall motion abnormalities and monocyte differences between two groups: those with death from cardiovascular toxicity and those without were statistically significant (all p < 0.05). 2) Univariate Cox regression identified diabetes (HR = 6.03, 95% CI 1.67~21.77, p = 0.006), Types of immune checkpoint inhibitors (HR = 6.62, 95% CI 1.69~25.89, p = 0.007), Echocardiographic ventricular wall motion abnormalities (HR = 4.61, 95% CI 1.19~17.85, p = 0.027), monocyte HR = 0.02, 95% CI 0.00~0.49, p = 0.015) as significant predictors. 3) Multivariate analysis confirmed monocyte (HR = 0.02, 95% CI 0.00~0.77, p = 0.036) as an independent predictor. 4) A predictive model for the risk of death from cardiovascular toxicity was constructed by including 4 variables (p < 0.05) from univariate Cox regression in a nomogram, with an AUC of 0.88 and 95% CI of 0.75 to 1.00. Conclusion: 1) Diabetes, Types of immune checkpoint inhibitors, Echocardiographic ventricular wall motion abnormalities and monocyte were significant predictors of death from cardiovascular toxicity. 2) Monocyte was an independent protective factor, after adjusting for other covariates. 3) A predictive model for the risk of cardiovascular toxic death was constructed by incorporating 4 variables from univariate Cox regression into a nomogram, and this model had good precision, discrimination, accuracy, and clinical benefit effects.展开更多
Hepatocellular carcinoma(HCC)is a highly aggressive malignancy,largely driven by an immunosuppres-sive tumor microenvironment(TME)that facilitates tumor growth,immune escape,and resistance to therapy.Although immunoth...Hepatocellular carcinoma(HCC)is a highly aggressive malignancy,largely driven by an immunosuppres-sive tumor microenvironment(TME)that facilitates tumor growth,immune escape,and resistance to therapy.Although immunotherapy—particularly immune checkpoint inhibitors(ICIs)—has transformed the therapeutic landscape by restoring T cell-mediated anti-tumor responses,their clinical benefit as monotherapy remains suboptimal.This limitation is primarily attributed to immunosuppressive components within the TME,including tumor-associated macrophages,regulatory T cells(Tregs),and myeloid-derived suppressor cells(MDSCs).To address these challenges,combination strategies have been explored,such as dual checkpoint blockade targeting programmed cell death protein 1(PD-1),programmed death-ligand 1(PD-L1),and cytotoxic T-lymphocyte-associated antigen 4(CTLA-4),as well as synergistic use of ICIs with anti-angiogenic agents or TME-targeted interventions.These approaches have shown encouraging potential in enhancing immune efficacy.This review outlines the complex crosstalk between the TME and immunotherapeutic responses in HCC,emphasizing how combination regimens may overcome immune resistance.Furthermore,we discuss the remaining hurdles,including therapeutic resistance and immune-related adverse events,and propose future directions involving TME-associated biomarkers and individualized treatment strategies to improve patient outcomes.展开更多
Non-small cell lung cancer(NSCLC)accounts for the majority of lung cancer cases and remains the leading cause of cancer-related mortality worldwide.Firstly,this review explores the limitations of conventional therapie...Non-small cell lung cancer(NSCLC)accounts for the majority of lung cancer cases and remains the leading cause of cancer-related mortality worldwide.Firstly,this review explores the limitations of conventional therapies,chemotherapy,radiotherapy,and surgery,focusing on the development of drug resistance and significant toxicity that often hinder their efficacy.Thereafter,advancements in targeted therapies,such as immune checkpoint inhibitors(ICIs)and tyrosine kinase inhibitors(TKIs),are discussed,highlighting their impact on improving outcomes for patients with specific genetic mutations,including c-ros oncogene 1 receptor tyrosine kinase(ROS1),anaplastic lymphoma kinase(ALK),and epidermal growth factor receptor(EGFR).Additionally,the emergence of novel immunotherapies and phytochemicals is examined,emphasizing their potential to overcome therapeutic resistance,particularly in advanced-stage diseases.The review also delves into the role of next-generation sequencing(NGS)in enabling personalized treatment approaches and explores the clinical potential of innovative agents,such as bispecific T-cell engagers(BiTEs)and antibody-drug conjugates(ADCs).Finally,we address the socioeconomic barriers that limit the accessibility of these therapies in low-resource settings and propose future research directions aimed at improving the long-term efficacy and accessibility of these treatments.展开更多
Background:immune checkpoint inhibitors(ICIs)have revolutionized the treatment of metastatic urothelial carcinoma(mUC),significantly improving survival outcomes.However,a subset of patients do not respond to ICIs,prom...Background:immune checkpoint inhibitors(ICIs)have revolutionized the treatment of metastatic urothelial carcinoma(mUC),significantly improving survival outcomes.However,a subset of patients do not respond to ICIs,prompting research into potential predictive factors.Commonly prescribed medications such as corticosteroids,proton-pump inhibitors(PPIs),antibiotics(Abs),antihypertensives,and analgesics may influence ICI effectiveness.Methods:we conducted a literature search on PubMed to investigate the impact of concomitant medications on the outcomes of patients with mUC,treated with ICIs.We selected the most relevant studies and performed a narrative review.Results:corticosteroids,PPIs and Abs have been associated with reduced survival in ICI-treated patients,including those with mUC.In contrast,antihypertensive agents like renin-angiotensin system inhibitors and betablockers may enhance ICI efficacy,though evidence remains inconclusive.The impact of other medications,such as statins,metformin,and analgesics,on ICI outcomes is less clear,with some data suggesting a detrimental impact on immune response.Conclusions:this narrative review synthesizes current evidence on how concomitant medications affect outcomes in mUC patients treated with ICIs.展开更多
全名:哥白尼期刊数据库(ICI World of Journal)、哥白尼精选期刊数据库(ICI Master List)所属国家及机构:波兰哥白尼国际数据机构(Index Copernicus International,简称ICI)收录形式及规模:创建于1999年,由波兰的Index Copernicus Inter...全名:哥白尼期刊数据库(ICI World of Journal)、哥白尼精选期刊数据库(ICI Master List)所属国家及机构:波兰哥白尼国际数据机构(Index Copernicus International,简称ICI)收录形式及规模:创建于1999年,由波兰的Index Copernicus International(ICI)组织运营。ICI World of Journals是全球第三大国际数据库。目前,数据库中注册的期刊超过4.5万种,每月使用人次超过7万,来自150个国家。期刊需先进入ICI World of Journals,方可申请ICI Master List的录入。展开更多
A new cyclic prefix(CP)-based nonoverlapping FBMC-QAM(CP-NO-FBMC-QAM)system with two prototype filters is proposed in this paper,which satisfies complex orthogonality conditions and good frequency energy confinement a...A new cyclic prefix(CP)-based nonoverlapping FBMC-QAM(CP-NO-FBMC-QAM)system with two prototype filters is proposed in this paper,which satisfies complex orthogonality conditions and good frequency energy confinement at the same time.We analyze its inter-carrier interference/inter-symbol interference(ICI/ISI)over multipath channels.Owing to the additional CP,the ISI of received symbols over multipath channels is eliminated in the proposed system,and the resulting improvement in the signal-to-interference ratio(SIR)performance is evaluated by theoretical analysis.Moreover,for the ICI caused by multipath propagation in received symbols,we develop a method that eliminates the ICI by frequency-domain channel estimation and equalization before the receiver filtering process.The proposed CP-NO-FBMC-QAM system and ICI cancellation method(ICICM)are validated by comparisons of implementation complexity,power spectral density(PSD),bit error rate(BER)and channel estimation performance with conventional CP-based orthogonal frequency division multiplexing(CP-OFDM)and FBMC-QAM systems.展开更多
SUMMARIES OF TOP NEWS STORIES 42nd Antarctic Expedition Kicked Off China’s 42nd Antarctic expedition team set sail from Shanghai on 1 November.During this expedition,a suite of new technologies will be deployed and t...SUMMARIES OF TOP NEWS STORIES 42nd Antarctic Expedition Kicked Off China’s 42nd Antarctic expedition team set sail from Shanghai on 1 November.During this expedition,a suite of new technologies will be deployed and tested in the icy wilderness of the Antarctic.展开更多
Background:Gastric Cancer(GC)is the 5th most prevalent and 4th most deadly neoplasm globally.Immunotherapy has emerged as a promising treatment approach in GC,potentially improving positive clinical outcomes while add...Background:Gastric Cancer(GC)is the 5th most prevalent and 4th most deadly neoplasm globally.Immunotherapy has emerged as a promising treatment approach in GC,potentially improving positive clinical outcomes while addressing the limitations of conventional therapies.GC immunotherapy modalities consist of adoptive cell therapy(ACT),cancer vaccines,and immune checkpoint inhibitors(ICI).Objectives:This systematic review aims to provide an overview of the advances in immune-based therapeutic approaches in GC,highlighting the potential of this therapy as a strategy for GC treatment.Methods:Key studies investigating several immunotherapeutic agents and combination therapies were searched in PUBMED and included in this study.Specific cancer outcomes related to disease progression or survival were analyzed.Results:After screening 236 studies,the results revealed that immunotherapy,particularly the ICI pembrolizumab,demonstrated promising efficacy in the treatment of GC,as several studies reported improved OS,PFS,and objective response rate with the use of pembrolizumab alone or in combination with other treatment modalities.Conclusion:Safety analysis showed that immunotherapy was mostly well-tolerated,with manageable adverse events and relatively good safety profiles.Nonetheless,further research is required to understand the mechanisms of tumor resistance better and identify predictive biomarkers that can direct treatment optimization.展开更多
文摘International Conference on Intelligent Systems（ICIS2005，2005年国际智能系统大会）于2005年12月1-3日在马来西亚吉隆坡举行。此次会议由马来西亚高等教育部批准，马来西来国家石油公司Petronas主赞助，Universiti Teknologi Petronas主办。参加会议的有来自中国、美国、日本、英国、马来西亚、印度等30个国家的200余篇论文作者及相关领域的研究人员。马来西来高等教育部部长Y．B．Dato’Sri Dr Haji Shafie Hj．Mohd Salleh亲临开幕式并致欢迎辞。
文摘创新是一个民族进步的灵魂,是国家兴旺发达的不竭动力。2017年创新研究国际会议（The International Conference on Innovation Studies,ICIS2017）将于2017年6月24—26日在清华大学经济管理学院召开。本会议由清华大学技术创新研究中心主任陈劲教授发起,国际创新学研究领域的著名领军学者、＂领先用户＂概念提出者Eric von Hippel教授作为特约嘉宾,将主持＂开放式创新与用户创新分会＂（1天）。
文摘目的:本研究目的旨在探讨抗PD-1/PD-L1 (程序性细胞死亡蛋白-1,Programmed cell death-1/程序性死亡配体-1,Programmed death-ligand 1)治疗后发生心血管毒性死亡的风险因素,并以此构建预测模型。方法:本研究为单中心回顾性研究,通过系统性回顾方法筛选2018年10月至2023年10月在青岛大学附属医院接受抗PD-1/PD-L1免疫治疗后的2665例实体肿瘤患者的病例资料观察180天,其中发生心血管毒性的33例,根据是否发生抗PD-1/PD-L1治疗心血管毒性死亡为结局,以是否发生死亡分为死亡组和存活组。采用单因素Cox回归分析其风险因素并控制相关混杂因素后构建预测模型绘制列线图。最后,利用受试者工作特征曲线(Receiver Operating Characteristic, ROC)、决策曲线分析法(Decision Curve Analysis, DCA)、校准曲线(Calibration Curve, CC)进行内部评价和内部验证。结果:1) 淋巴细胞计数、单核细胞计数、血小板计数、合并糖尿病、免疫检查点抑制剂种类、彩超室壁运动异常在心血管毒性存活组和死亡组间的差异均有统计学意义(均p Purpose: This study aimed to investigate risk factors for death from cardiovascular toxicity following anti-PD-1/PD-L1 therapy and develop a predictive model. Methods: This study was a single-center retrospective study, which screened the case data of 2665 patients with solid tumors after receiving anti-PD-1/PD-L1 immunotherapy at the Affiliated Hospital of Qingdao University for 180 days of observation by a systematic retrospective method, 33 cases of cardiovascular toxicity, and the outcome was based on whether or not death from cardiovascular toxicity of anti-PD-1/PD-L1 therapy occurred as the outcome categorized into death and survival groups. A one-way Cox regression analysis was used to analyze the risk factors and control for relevant confounders, and a predictive model was constructed to draw a column-line graph. Finally, Receiver Operating Characteristic (ROC), Decision Curve Analysis (DCA), and Calibration Curve (CC) were used for internal evaluation and internal validation. Results: 1) Lymphocyte, Platelet, Diabetes, Types of immune checkpoint inhibitors, Echocardiographic ventricular wall motion abnormalities and monocyte differences between two groups: those with death from cardiovascular toxicity and those without were statistically significant (all p < 0.05). 2) Univariate Cox regression identified diabetes (HR = 6.03, 95% CI 1.67~21.77, p = 0.006), Types of immune checkpoint inhibitors (HR = 6.62, 95% CI 1.69~25.89, p = 0.007), Echocardiographic ventricular wall motion abnormalities (HR = 4.61, 95% CI 1.19~17.85, p = 0.027), monocyte HR = 0.02, 95% CI 0.00~0.49, p = 0.015) as significant predictors. 3) Multivariate analysis confirmed monocyte (HR = 0.02, 95% CI 0.00~0.77, p = 0.036) as an independent predictor. 4) A predictive model for the risk of death from cardiovascular toxicity was constructed by including 4 variables (p < 0.05) from univariate Cox regression in a nomogram, with an AUC of 0.88 and 95% CI of 0.75 to 1.00. Conclusion: 1) Diabetes, Types of immune checkpoint inhibitors, Echocardiographic ventricular wall motion abnormalities and monocyte were significant predictors of death from cardiovascular toxicity. 2) Monocyte was an independent protective factor, after adjusting for other covariates. 3) A predictive model for the risk of cardiovascular toxic death was constructed by incorporating 4 variables from univariate Cox regression into a nomogram, and this model had good precision, discrimination, accuracy, and clinical benefit effects.
基金supported by Guangdong Basic and Applied Basic Research Foundation(2024A1515012993)the Project of Hunan Provincial Health Commission(No.D202303078877).
文摘Hepatocellular carcinoma(HCC)is a highly aggressive malignancy,largely driven by an immunosuppres-sive tumor microenvironment(TME)that facilitates tumor growth,immune escape,and resistance to therapy.Although immunotherapy—particularly immune checkpoint inhibitors(ICIs)—has transformed the therapeutic landscape by restoring T cell-mediated anti-tumor responses,their clinical benefit as monotherapy remains suboptimal.This limitation is primarily attributed to immunosuppressive components within the TME,including tumor-associated macrophages,regulatory T cells(Tregs),and myeloid-derived suppressor cells(MDSCs).To address these challenges,combination strategies have been explored,such as dual checkpoint blockade targeting programmed cell death protein 1(PD-1),programmed death-ligand 1(PD-L1),and cytotoxic T-lymphocyte-associated antigen 4(CTLA-4),as well as synergistic use of ICIs with anti-angiogenic agents or TME-targeted interventions.These approaches have shown encouraging potential in enhancing immune efficacy.This review outlines the complex crosstalk between the TME and immunotherapeutic responses in HCC,emphasizing how combination regimens may overcome immune resistance.Furthermore,we discuss the remaining hurdles,including therapeutic resistance and immune-related adverse events,and propose future directions involving TME-associated biomarkers and individualized treatment strategies to improve patient outcomes.
文摘Non-small cell lung cancer(NSCLC)accounts for the majority of lung cancer cases and remains the leading cause of cancer-related mortality worldwide.Firstly,this review explores the limitations of conventional therapies,chemotherapy,radiotherapy,and surgery,focusing on the development of drug resistance and significant toxicity that often hinder their efficacy.Thereafter,advancements in targeted therapies,such as immune checkpoint inhibitors(ICIs)and tyrosine kinase inhibitors(TKIs),are discussed,highlighting their impact on improving outcomes for patients with specific genetic mutations,including c-ros oncogene 1 receptor tyrosine kinase(ROS1),anaplastic lymphoma kinase(ALK),and epidermal growth factor receptor(EGFR).Additionally,the emergence of novel immunotherapies and phytochemicals is examined,emphasizing their potential to overcome therapeutic resistance,particularly in advanced-stage diseases.The review also delves into the role of next-generation sequencing(NGS)in enabling personalized treatment approaches and explores the clinical potential of innovative agents,such as bispecific T-cell engagers(BiTEs)and antibody-drug conjugates(ADCs).Finally,we address the socioeconomic barriers that limit the accessibility of these therapies in low-resource settings and propose future research directions aimed at improving the long-term efficacy and accessibility of these treatments.
文摘Background:immune checkpoint inhibitors(ICIs)have revolutionized the treatment of metastatic urothelial carcinoma(mUC),significantly improving survival outcomes.However,a subset of patients do not respond to ICIs,prompting research into potential predictive factors.Commonly prescribed medications such as corticosteroids,proton-pump inhibitors(PPIs),antibiotics(Abs),antihypertensives,and analgesics may influence ICI effectiveness.Methods:we conducted a literature search on PubMed to investigate the impact of concomitant medications on the outcomes of patients with mUC,treated with ICIs.We selected the most relevant studies and performed a narrative review.Results:corticosteroids,PPIs and Abs have been associated with reduced survival in ICI-treated patients,including those with mUC.In contrast,antihypertensive agents like renin-angiotensin system inhibitors and betablockers may enhance ICI efficacy,though evidence remains inconclusive.The impact of other medications,such as statins,metformin,and analgesics,on ICI outcomes is less clear,with some data suggesting a detrimental impact on immune response.Conclusions:this narrative review synthesizes current evidence on how concomitant medications affect outcomes in mUC patients treated with ICIs.
文摘全名:哥白尼期刊数据库(ICI World of Journal)、哥白尼精选期刊数据库(ICI Master List)所属国家及机构:波兰哥白尼国际数据机构(Index Copernicus International,简称ICI)收录形式及规模:创建于1999年,由波兰的Index Copernicus International(ICI)组织运营。ICI World of Journals是全球第三大国际数据库。目前,数据库中注册的期刊超过4.5万种,每月使用人次超过7万,来自150个国家。期刊需先进入ICI World of Journals,方可申请ICI Master List的录入。
文摘A new cyclic prefix(CP)-based nonoverlapping FBMC-QAM(CP-NO-FBMC-QAM)system with two prototype filters is proposed in this paper,which satisfies complex orthogonality conditions and good frequency energy confinement at the same time.We analyze its inter-carrier interference/inter-symbol interference(ICI/ISI)over multipath channels.Owing to the additional CP,the ISI of received symbols over multipath channels is eliminated in the proposed system,and the resulting improvement in the signal-to-interference ratio(SIR)performance is evaluated by theoretical analysis.Moreover,for the ICI caused by multipath propagation in received symbols,we develop a method that eliminates the ICI by frequency-domain channel estimation and equalization before the receiver filtering process.The proposed CP-NO-FBMC-QAM system and ICI cancellation method(ICICM)are validated by comparisons of implementation complexity,power spectral density(PSD),bit error rate(BER)and channel estimation performance with conventional CP-based orthogonal frequency division multiplexing(CP-OFDM)and FBMC-QAM systems.
文摘SUMMARIES OF TOP NEWS STORIES 42nd Antarctic Expedition Kicked Off China’s 42nd Antarctic expedition team set sail from Shanghai on 1 November.During this expedition,a suite of new technologies will be deployed and tested in the icy wilderness of the Antarctic.
文摘Background:Gastric Cancer(GC)is the 5th most prevalent and 4th most deadly neoplasm globally.Immunotherapy has emerged as a promising treatment approach in GC,potentially improving positive clinical outcomes while addressing the limitations of conventional therapies.GC immunotherapy modalities consist of adoptive cell therapy(ACT),cancer vaccines,and immune checkpoint inhibitors(ICI).Objectives:This systematic review aims to provide an overview of the advances in immune-based therapeutic approaches in GC,highlighting the potential of this therapy as a strategy for GC treatment.Methods:Key studies investigating several immunotherapeutic agents and combination therapies were searched in PUBMED and included in this study.Specific cancer outcomes related to disease progression or survival were analyzed.Results:After screening 236 studies,the results revealed that immunotherapy,particularly the ICI pembrolizumab,demonstrated promising efficacy in the treatment of GC,as several studies reported improved OS,PFS,and objective response rate with the use of pembrolizumab alone or in combination with other treatment modalities.Conclusion:Safety analysis showed that immunotherapy was mostly well-tolerated,with manageable adverse events and relatively good safety profiles.Nonetheless,further research is required to understand the mechanisms of tumor resistance better and identify predictive biomarkers that can direct treatment optimization.
